ESTRO 2024 - Abstract Book

S2022

Clinical - Paediatric

ESTRO 2024

but recovered after treatment with steroids and one patient had a rapid onset of loss of vision. No patients experienced late grade ≥3 side effects.

Conclusion:

The implementation of national guidelines has harmonised the way paediatric patients with recurrent CNS tumours are treated with re-irradiation in Sweden. A structured follow-up shows that severe side effects are rare, and that re-irradiation should be considered a treatment option that can offer relief of symptoms and/or local control for selected patients.

Keywords: re-irradiation, CNS-tumours, paediatric

References:

1. Embring A, Blomstrand M, Asklid A, Nilsson MP, Agrup M, Svard AM, et al. Re-irradiation in Paediatric Tumours of the Central Nervous System: National Guidelines from the Swedish Workgroup of Paediatric Radiotherapy. Clin Oncol (R Coll Radiol). 2023. Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG, et al. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022;23(10):e469 e78. 2.

625

Digital Poster

Distractive method without anaesthesia for paediatric treatments

10 year-Experience of Caen Centre